查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1716441

糖尿病藥物市場至2032年的預測：按產品、糖尿病類型、形式、分銷管道和地區的全球分析

Diabetes Drugs Market Forecasts to 2032 - Global Analysis By Product (Insulin, Oral Anti-Diabetic Drugs, Injectable Non-Insulin Drugs and Combination Drugs), Diabetes Type, Formulation, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，全球糖尿病藥物市場在2025年達到 943億美元，預計到2032年將達到 1,736億美元，預測期內的年複合成長率為 9.1%。

抗糖尿病藥物是用來控制糖尿病患者血糖值的藥物。這些藥物透過多種機制發揮作用，包括刺激胰島素分泌、改善胰島素敏感性、抑制葡萄糖吸收和增加尿糖排泄。這些藥物分為不同類別 - 胰島素製劑、GLP-1受體促效劑、SGLT2抑制劑和口服降血糖藥物 - 並根據1型或2型糖尿病患者的特定需求量身定做。透過調節血糖濃度，這些藥物有助於預防糖尿病相關併發症，如心血管和神經病變。配方的不斷進步目的是提高療效和患者治療效果。

根據國際糖尿病聯盟（IDF）提供的最新資料，2021年，全球20-79歲成年人中有5.37億人被診斷出患有糖尿病。預計到2030年這數字將達到6.43億，到2045年將達到7.83億。

全球糖尿病盛行率上升

都市化加快、久坐不動的生活方式和不健康的飲食習慣是導致第1 型和第2 型糖尿病發病率上升的主要原因。診斷工具和早期檢測技術的進步對有效治療的需求更大。此外，包括長效胰島素製劑和聯合治療在內的藥物開發的快速進展提高治療的有效性和便利性。目的是傳播糖尿病意識和鼓勵定期健康檢查的公共衛生措施對市場產生積極影響。

糖尿病藥物高成本

高級胰島素製劑和口服抗糖尿病藥物價格高昂，限制了人們的負擔能力，尤其是在中低收入地區。複雜的製造流程和嚴格的監管要求推高了生產成本，影響了供應和定價。農村和低度開發地區醫療服務有限，進一步限制了人們獲得優質糖尿病管理解決方案的機會。大致上，這些因素阻礙了尖端糖尿病藥物的廣泛應用，並限制了市場成長潛力。

個人化醫療和客製化治療方案日益普及

基因檢測和生物標記識別的進步使醫療保健專業人員能夠根據患者的個別需求量身定做治療方法。穿戴式胰島素幫浦和智慧注射器等藥物傳輸系統的持續技術創新將提高患者的便利性和對治療方法的依從性。擴大基因療法和再生醫學等替代療法的研究將開闢新的成長途徑。這種對改善健康結果和減少併發症的關注推動個人化解決方案的採用。

來自學名藥和替代療法的競爭

廣泛使用的藥物的低成本學名藥的出現影響了品牌藥物的市場佔有率和收益。非藥物干預，例如飲食調整和運動計劃，通常可以提供補充解決方案並減少藥物依賴。圍繞實驗性糖尿病治療及其長期有效性的倫理問題可能會破壞消費者的信任。此外，地緣政治緊張局勢和貿易限制可能會擾亂製藥生產所用關鍵成分和原料的供應鏈。

COVID-19的影響：

COVID-19 疫情影響了供應鏈和醫療保健系統，擾亂了糖尿病藥物市場。生產延誤和物流挑戰限制了藥品的獲取，導致一些地區出現藥品短缺。在關閉期間，醫院就診次數減少和常規檢查延遲影響了糖尿病的診斷和治療。然而，這場大流行凸顯了糖尿病患者面臨嚴重後果的脆弱性，並促使人們提高對糖尿病管理的認知和重視。

口服糖尿病藥物市場預計將在預測期內實現最大幅度成長

口服抗糖尿病藥物由於其便利性和廣泛使用，預計在預測期內將佔據最大的市場佔有率。這些藥物包括雙胍類和 DPP-4 抑制劑，可有效控制血糖，且易於服用，因此深受患者歡迎。配方和聯合治療的進步進一步提高了治療效果並減少了副作用。糖尿病高發生率地區的採用率不斷提高以及宣傳宣傳活動的加強也促進了該領域的持續成長。

預計生物相似藥胰島素製劑領域在預測期內將以最高年複合成長率成長

由於擴大採用具有成本效益的品牌胰島素製劑替代品，預計生物相似藥胰島素領域將在預測期內實現最高成長率。生物相似藥胰島素具有相當的安全性和有效性，對於希望降低治療成本的醫療保健提供者來說是一個有吸引力的選擇。監管部門的核准和新型生物相似藥的進入推動該市場的成長。

佔有率最大的地區

由於糖尿病盛行率高且醫療保健投資不斷增加，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和日本等國家由於糖尿病患者數量龐大且醫療服務覆蓋範圍不斷擴大而在該地區佔據主導地位。目的是改善糖尿病管理的政府措施和宣傳宣傳活動進一步推動了市場成長。該地區強大的製藥生產能力和對可負擔治療的關注確保了其持續的市場主導。

年複合成長率最高的地區：

在預測期內，由於糖尿病治療技術和研究的重大進步，預計北美將呈現最高的年複合成長率。主要企業的存在和強大的醫療保健基礎設施支持了藥物開發的創新。由於生活方式的改變，糖尿病盛行率不斷上升，推動了對有效且易於獲得的藥物的需求。此外，優惠的償付政策和生物相似藥胰島素的日益普及也促進了市場的成長。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之1：

  • 公司簡介
    • 對其他市場公司（最多3家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場走勢分析

  • 促進因素
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭敵對

第5章 全球糖尿病藥物市場（依產品）

  • 胰島素
    • 速效胰島素
      • Insulin Aspart
      • Insulin Lispro
      • Insulin Glulisine
    • 長效胰島素
      • Insulin Detemir
      • Insulin Degludec
    • 速效胰島素
      • Humulin R
      • Novolin R
    • 中效胰島素
  • 口服抗糖尿病藥物
    • 雙胍類
    • 磺醯尿素類
    • 胰島素增敏劑（TZD）
    • DPP-4抑制劑
    • SGLT-2抑制劑
    • α-Glucosidase酶抑制劑
  • 胰島素以外的注射藥物
    • GLP-1受體促效劑
    • Amylin 類似物
  • 伴隨用藥

第6章 全球糖尿病藥物市場（依糖尿病類型）

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病
  • 糖尿病前期/葡萄糖耐受不良

第7章 全球糖尿病藥物市場（依形式）

  • 管瓶
  • 筆
  • 泵浦
  • 生物相似藥胰島素
  • 其他形式

第8章 全球糖尿病藥物市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他通路

第9章 全球糖尿病藥物市場（依地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Abbott
  • Adocia
  • Amgen
  • AstraZeneca
  • Bayers AG
  • Biocon
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co.
  • Mylan
  • Novartis
  • Novo Nordisk
  • Peptron
  • Pfizer
  • Sanofi
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
Product Code: SMRC29252

According to Stratistics MRC, the Global Diabetes Drugs Market is accounted for $94.3 billion in 2025 and is expected to reach $173.6 billion by 2032 growing at a CAGR of 9.1% during the forecast period. Diabetes drugs are medications designed to manage blood sugar levels in individuals with diabetes mellitus. These drugs work through various mechanisms, such as enhancing insulin secretion, improving insulin sensitivity, reducing glucose absorption, or increasing glucose excretion via urine. They are categorized into different classes, including insulin, GLP-1 receptor agonists, SGLT2 inhibitors, and oral hypoglycemic agents, tailored to the specific needs of Type 1 or Type 2 diabetes patients. By regulating glucose levels, these medications help prevent complications associated with diabetes, such as cardiovascular issues and nerve damage. Continuous advancements in drug formulations aim to improve efficacy and patient outcomes.

According to the latest data provided by the International Diabetes Federation (IDF), in 2021, 537 million adults aged 20-79 years were diagnosed with diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Rising prevalence of diabetes globally

Increased urbanization, sedentary lifestyles, and unhealthy eating habits have significantly contributed to the growing incidence of Type 1 and Type 2 diabetes. Advances in diagnostic tools and early detection technologies further raise the demand for effective treatments. Moreover, rapid advancements in drug development, including long-acting insulin formulations and combination therapies, boost treatment efficacy and convenience. Public health initiatives aimed at spreading diabetes awareness and promoting regular health check-ups have positively impacted the market.

Restraint:

High costs associated with diabetes medications

Premium pricing of advanced insulin and oral anti-diabetic drugs limits affordability, especially in low- and middle-income regions. Complex manufacturing processes and strict regulatory requirements add to production expenses, impacting supply and pricing dynamics. Limited availability of healthcare services in rural and underdeveloped areas further restricts access to quality diabetes management solutions. These factors collectively hinder the widespread adoption of cutting-edge diabetes drugs and constrain the market's growth potential.

Opportunity:

Growing popularity of personalized medicine and tailored treatment plans

Advances in genetic testing and biomarker identification enable healthcare professionals to customize therapies based on individual patient needs. Continuous innovation in drug delivery systems, such as wearable insulin pumps and smart injectors, enhances patient convenience and adherence to treatment regimens. Expanding research into alternative treatments, including gene therapy and regenerative medicine, opens new avenues for growth. Thus the focus on improving health outcomes and minimizing complications boosts the adoption of personalized solutions.

Threat:

Competition from generic drugs and alternative therapies

The availability of low-cost generic versions of widely used medications impacts market share and revenue for branded drugs. Non-pharmaceutical interventions, such as dietary adjustments and exercise programs, often provide complementary solutions, reducing dependency on drugs. Ethical concerns surrounding experimental diabetes treatments and their long-term efficacy can undermine consumer confidence. Furthermore geopolitical tensions and trade restrictions may disrupt the supply chain for critical ingredients and raw materials used in drug manufacturing.

Covid-19 Impact:

The COVID-19 pandemic disrupted the diabetes drugs market by affecting supply chains and healthcare delivery systems. Manufacturing delays and logistics challenges limited the availability of medications, creating shortages in some regions. Reduced hospital visits and postponed routine check-ups during lockdowns affected diabetes diagnosis and treatment initiation. However, the pandemic highlighted the vulnerability of diabetic patients to severe COVID-19 outcomes, prompting increased awareness and prioritization of diabetes management.

The oral anti-diabetic drugs segment is expected to be the largest during the forecast period

The oral anti-diabetic drugs segment is expected to account for the largest market share during the forecast period due to their convenience and widespread use. These medications, including biguanides and DPP-4 inhibitors, offer effective glycemic control and ease of administration, driving their popularity among patients. Advancements in drug formulations and combination therapies further enhance treatment efficacy and reduce side effects. Increased adoption in regions with high diabetes prevalence, coupled with growing awareness campaigns, contributes to the segment's sustained growth.

The biosimilar insulins segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biosimilar insulins segment is predicted to witness the highest growth rate driven by increasing adoption of cost-effective alternatives to branded insulin products. Biosimilar insulins offer comparable safety and efficacy, making them an attractive option for healthcare providers aiming to reduce treatment costs. Regulatory approvals and market entry of new biosimilars have accelerated growth in this market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to high prevalence of diabetes and increasing healthcare investments. Countries such as China, India, and Japan dominate the region due to their large diabetic populations and expanding access to healthcare services. Government initiatives aimed at improving diabetes management and awareness campaigns further drive market growth. The region's strong pharmaceutical manufacturing capabilities and focus on affordable treatments ensure sustained market leadership.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by significant advancements in diabetes treatment technologies and research. The presence of leading pharmaceutical companies and robust healthcare infrastructure supports innovation in drug development. Rising prevalence of diabetes due to lifestyle changes enhances demand for effective and accessible medications. Additionally favourable reimbursement policies and increased adoption of biosimilar insulins contribute to market growth.

Key players in the market

Some of the key players in Diabetes Drugs Market include Abbott, Adocia, Amgen, AstraZeneca, Bayer AG, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Merck & Co., Mylan, Novartis, Novo Nordisk, Peptron, Pfizer, Sanofi, Sun Pharmaceuticals and Takeda Pharmaceuticals.

Key Developments:

In April 2025, Novo Nordisk announced a $1.09 billion investment to expand its manufacturing facility in Minas Gerais, Brazil. This expansion aims to significantly increase the production capacity of injectable medications for obesity, diabetes, and other chronic diseases, with operations expected to commence by 2028.

In March 2025, Biocon entered into an exclusive licensing and supply agreement with Brazil-based Biomm SA for the commercialization of Semaglutide, a drug used to improve glycemic control in adults with type-2 diabetes.

In February 2025, Dr. Reddy's Laboratories received approval from the Central Drug Standard Control Organisation (CDSCO) to conduct a Phase III clinical trial evaluating the efficacy, safety, and tolerability of its oral Semaglutide tablets compared to RYBELSUS (Semaglutide) tablets in adult patients with inadequately controlled type-2 diabetes mellitus.

Products Covered:

  • Insulin
  • Oral Anti-Diabetic Drugs
  • Injectable Non-Insulin Drugs
  • Combination Drugs

Diabetes Types Covered:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes / Impaired Glucose Tolerance

Formulations Covered:

  • Vials
  • Pens
  • Pumps
  • Biosimilar Insulins
  • Other Formulations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetes Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Insulin
    • 5.2.1 Rapid-Acting Insulin
      • 5.2.1.1 Insulin Aspart
      • 5.2.1.2 Insulin Lispro
      • 5.2.1.3 Insulin Glulisine
    • 5.2.2 Long-Acting Insulin
      • 5.2.2.1 Insulin Detemir
      • 5.2.2.2 Insulin Degludec
    • 5.2.3 Short-Acting Insulin
      • 5.2.3.1 Humulin R
      • 5.2.3.2 Novolin R
    • 5.2.4 Intermediate-Acting Insulin
  • 5.3 Oral Anti-Diabetic Drugs
    • 5.3.1 Biguanides
    • 5.3.2 Sulfonylureas
    • 5.3.3 Thiazolidinediones (TZDs)
    • 5.3.4 DPP-4 Inhibitors
    • 5.3.5 SGLT-2 Inhibitors
    • 5.3.6 Alpha-glucosidase Inhibitors
  • 5.4 Injectable Non-Insulin Drugs
    • 5.4.1 GLP-1 Receptor Agonists
    • 5.4.2 Amylin Analogs
  • 5.5 Combination Drugs

6 Global Diabetes Drugs Market, By Diabetes Type

  • 6.1 Introduction
  • 6.2 Type 1 Diabetes
  • 6.3 Type 2 Diabetes
  • 6.4 Gestational Diabetes
  • 6.5 Prediabetes / Impaired Glucose Tolerance

7 Global Diabetes Drugs Market, By Formulation

  • 7.1 Introduction
  • 7.2 Vials
  • 7.3 Pens
  • 7.4 Pumps
  • 7.5 Biosimilar Insulins
  • 7.6 Other Formulations

8 Global Diabetes Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Diabetes Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Adocia
  • 11.3 Amgen
  • 11.4 AstraZeneca
  • 11.5 Bayers AG
  • 11.6 Biocon
  • 11.7 Boehringer Ingelheim
  • 11.8 Bristol Myers Squibb
  • 11.9 Dr. Reddy's Laboratories
  • 11.10 Eli Lilly
  • 11.11 Johnson & Johnson
  • 11.12 Merck & Co.
  • 11.13 Mylan
  • 11.14 Novartis
  • 11.15 Novo Nordisk
  • 11.16 Peptron
  • 11.17 Pfizer
  • 11.18 Sanofi
  • 11.19 Sun Pharmaceuticals
  • 11.20 Takeda Pharmaceuticals

List of Tables

  • Table 1 Global Diabetes Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Diabetes Drugs Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Diabetes Drugs Market Outlook, By Insulin (2024-2032) ($MN)
  • Table 4 Global Diabetes Drugs Market Outlook, By Rapid-Acting Insulin (2024-2032) ($MN)
  • Table 5 Global Diabetes Drugs Market Outlook, By Insulin Aspart (2024-2032) ($MN)
  • Table 6 Global Diabetes Drugs Market Outlook, By Insulin Lispro (2024-2032) ($MN)
  • Table 7 Global Diabetes Drugs Market Outlook, By Insulin Glulisine (2024-2032) ($MN)
  • Table 8 Global Diabetes Drugs Market Outlook, By Long-Acting Insulin (2024-2032) ($MN)
  • Table 9 Global Diabetes Drugs Market Outlook, By Insulin Detemir (2024-2032) ($MN)
  • Table 10 Global Diabetes Drugs Market Outlook, By Insulin Degludec (2024-2032) ($MN)
  • Table 11 Global Diabetes Drugs Market Outlook, By Short-Acting Insulin (2024-2032) ($MN)
  • Table 12 Global Diabetes Drugs Market Outlook, By Humulin R (2024-2032) ($MN)
  • Table 13 Global Diabetes Drugs Market Outlook, By Novolin R (2024-2032) ($MN)
  • Table 14 Global Diabetes Drugs Market Outlook, By Intermediate-Acting Insulin (2024-2032) ($MN)
  • Table 15 Global Diabetes Drugs Market Outlook, By Oral Anti-Diabetic Drugs (2024-2032) ($MN)
  • Table 16 Global Diabetes Drugs Market Outlook, By Biguanides (2024-2032) ($MN)
  • Table 17 Global Diabetes Drugs Market Outlook, By Sulfonylureas (2024-2032) ($MN)
  • Table 18 Global Diabetes Drugs Market Outlook, By Thiazolidinediones (TZDs) (2024-2032) ($MN)
  • Table 19 Global Diabetes Drugs Market Outlook, By DPP-4 Inhibitors (2024-2032) ($MN)
  • Table 20 Global Diabetes Drugs Market Outlook, By SGLT-2 Inhibitors (2024-2032) ($MN)
  • Table 21 Global Diabetes Drugs Market Outlook, By Alpha-glucosidase Inhibitors (2024-2032) ($MN)
  • Table 22 Global Diabetes Drugs Market Outlook, By Injectable Non-Insulin Drugs (2024-2032) ($MN)
  • Table 23 Global Diabetes Drugs Market Outlook, By GLP-1 Receptor Agonists (2024-2032) ($MN)
  • Table 24 Global Diabetes Drugs Market Outlook, By Amylin Analogs (2024-2032) ($MN)
  • Table 25 Global Diabetes Drugs Market Outlook, By Combination Drugs (2024-2032) ($MN)
  • Table 26 Global Diabetes Drugs Market Outlook, By Diabetes Type (2024-2032) ($MN)
  • Table 27 Global Diabetes Drugs Market Outlook, By Type 1 Diabetes (2024-2032) ($MN)
  • Table 28 Global Diabetes Drugs Market Outlook, By Type 2 Diabetes (2024-2032) ($MN)
  • Table 29 Global Diabetes Drugs Market Outlook, By Gestational Diabetes (2024-2032) ($MN)
  • Table 30 Global Diabetes Drugs Market Outlook, By Prediabetes / Impaired Glucose Tolerance (2024-2032) ($MN)
  • Table 31 Global Diabetes Drugs Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 32 Global Diabetes Drugs Market Outlook, By Vials (2024-2032) ($MN)
  • Table 33 Global Diabetes Drugs Market Outlook, By Pens (2024-2032) ($MN)
  • Table 34 Global Diabetes Drugs Market Outlook, By Pumps (2024-2032) ($MN)
  • Table 35 Global Diabetes Drugs Market Outlook, By Biosimilar Insulins (2024-2032) ($MN)
  • Table 36 Global Diabetes Drugs Market Outlook, By Other Formulations (2024-2032) ($MN)
  • Table 37 Global Diabetes Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 38 Global Diabetes Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 39 Global Diabetes Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 40 Global Diabetes Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 41 Global Diabetes Drugs Market Outlook, By Other Distribution Channels (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.